Nutrition news

Innovative research grant in parenteral nutrition of € 250,000 awarded by Fresenius Kabi


This year’s winner is Professor Stefan Schaller Director General of Charity – Universitätsmedizin Berlin, germany, for his proposal entitled “Improvement of muscle metabolism by a combination of muscle activation and protein substitution”. This cutting-edge study aims to explore the effect of protein substitution before and after targeted early mobilization in the acute phase of severe disease. The announcement was made at the congress of the European Society for Clinical Nutrition and Metabolism (ESPEN).

During the virtual awards ceremony, Prof. Schaller said: “After working on this research proposal for a long time, my research team and I are delighted to be able to now conduct the study, and I am very grateful for the generous grant from Fresenius Kabi. I am very optimistic that this trial will have an impact on nutritional therapy in critical care. “

Professor Schaller took part in the program alongside 18 other participants from around the world, including representatives from Africa, Asia, Australia, Europe, New Zealand, and North and South America. After four training sessions, the participants presented their research proposals to an independent international scientific committee, made up of five leading experts: the professor Mette Berger, Switzerland; Professor Olav Rooyackers, Sweden; Professor Tim Friede, Germany; Professor Robert martindale, United States; and teacher Ho-Seong Han, South Korea. The committee was impressed with the high level of quality of all submissions, which made the selection of a winner extremely difficult.

Dr Jos Simons, Executive Vice President of Fresenius Kabi, said: “We are absolutely delighted to be able to award this fellowship to Professor Schaller. The scientific committee and Fresenius Kabi were stunned by his proposal and the positive impact it will have on clinical practice. We are very pleased that Professor Schaller is starting this clinical study. “

This is the second JUMPstart research grant worth € 250,000. The first 19-participant program completed in 2019, with the dietician scholarship awarded Lizl Veldsman, Tygerberg University Hospital in Cape Town, South Africa.

With the JUMPstart training program and research grant, Fresenius Kabi is supporting the next generation of clinical experts who will help advance nutritional therapy in critically ill patients.

Fresenius Kabi is a global healthcare company specializing in life-saving drugs and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio includes a full line of generic IV drugs, infusion therapy and clinical nutrition products as well as delivery devices for these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, Fresenius Kabi’s first biosimilar product was launched. In the field of transfusion medicine and cell therapy, Fresenius Kabi offers products for the collection of blood components and extracorporeal therapies.

With its business philosophy of “taking care of life”, the company is committed to putting essential drugs and technologies in the hands of the people who help patients and to find the best answers to the challenges they face.

Fresenius Kabi employs around 40,500 people worldwide. In 2020, the company achieved a turnover of approximately 7.0 billion euros. Fresenius Kabi AG is a 100% subsidiary of the healthcare group Fresenius SE & Co. KGaA.

For more information, please visit www.fresenius-kabi.com

This press release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, for example changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, fluctuations in currency exchange rates, uncertainties in litigation or investigative procedures; and the availability of funding. Fresenius Kabi assumes no responsibility for updating any forward-looking statements contained in this press release.

Board of Directors: Michel Sen (Chairman), Marc Crouton, John ducker, Dr Oskar Haszonits, Dr. Christian Hauer, Dr Michael Schönhofen, Gerrit Steen

Chairman of the Supervisory Board : Stephan Sturm

Headquarters: Bad Homburg, Germany

Commercial register: Amtsgericht Bad Homburg – HRB 11654

Emese Kamp
CARROTS ROSE Communications GmbH
E-mail: [email protected]
Telephone: +49 69 4272 614-141

Photo – https://mma.prnewswire.com/media/1693173/Fresenius_Kabi.jpg
Logo – https://mma.prnewswire.com/media/1655430/Fresenius_Kabi_Logo.jpg

SOURCE Fresenius Kabi

Related links

https://www.fresenius-kabi.com